Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Aug 09, 2021 8:35am
53 Views
Post# 33670855

RE:100M$ cash voucher (non dilutive) on 90M$ market cap

RE:100M$ cash voucher (non dilutive) on 90M$ market cap

$3.45 is better than $2.86 but it's not 2x or 3x times the $4 that you were pumping...  let's see where it goes but without R&D milestones except preclinical. Nothing on 4050/ Fez MAD studies for new indications to take to clinic and they then need to get clinical trial design complete working with FDA and recruit patients, etc. Not enough runway... 

tommyjones1 wrote:

sp will 2x,3x easy thats why these clowns want your shares. Now, when is it coming? See latest NR: the Rare Pediatric Disease Priority Review Voucher ("PRV") by its subsidiary, Prometic Biotherapeutics Inc. ("PBT"), which would be payable to Liminal prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT (the "Second Closing").

 

coming anytime...

-----------------------------------------------------------------------------------------------------------------

everybody on this board and the market manipulators want your shares... this stock wil ride high next days... 

With this FDA ok, we can sell that riplazym voucher...market price is between 80M$-120M$ u.s., so lets say 100M$ u.s., we get 70%.... 70M$ u.s. + 17M$ u.s. we cashed already, around 100M$ can$ , lmnl will be able to execute big time and do more deals like this (sell or partner), we gat some in the oven already. Doyour dd. Dont listen to the clown$ operating on this board.  They are here for $$$... accumulation time....




<< Previous
Bullboard Posts
Next >>